The purpose of the study was to evaluate the potential additive effect of treating erectile dysfunction (ED) patients with both PT-141, which initiates erections via a central nervous system mechanism of action, and Pfizer’s Viagra, a peripheral vasodilator indicated for erectile dysfunction.
Doses of either 50mg or 100mg Viagra were administered to 32 ED patients with or without PT-141 (7.5mg or 10mg). Each patient’s erectile activity was monitored for six hours using a RigiScan device.
The duration of erectile activity measured after co-administration of each combination of PT-141 was significantly enhanced compared to that observed with the relevant dose of Viagra alone.
Furthermore, co-administration of PT-141 and Viagra did not result in any serious or significant adverse events.
“The co-administration of PT- 141 and Viagra may constitute an important treatment alternative for ED patients in whom higher doses of a single therapy are not effective or are not well-tolerated,” said Dr Carl Spana, president and CEO of Palatin. “Additionally, the results of this study support the proposed mechanism of action for PT-141.”